AADA says final 2027 Medicare rule cuts dermatology pay about 6%; TYK2 inhibitor nomelcitinib meets phase 3 psoriasis goals

• Payment Nov 5, 2026
  Final 2027 Medicare fee schedule cuts dermatology payments about 6%, AADA says
  The American Academy of Dermatology Association (AADA) said the calendar year 2027 physician fee schedule final rule from the Centers for Medicare & Medicaid Services (CMS) will "result in the largest cut ever imposed on skin cancer care," according to its president, Dr. Murad Alam, with reductions for same-day care compounded by practice expense adjustments. Dermatology Times reported the AADA's initial estimate of an approximately 6% reduction in Medicare payments for dermatologists. The rule sets the conversion factor at $32.63 for clinicians outside qualifying alternative payment models, a 2.31% decrease, according to CMS.
  Sources: AADA, Dermatology Times, CMS
• Research Nov 3, 2026
  TYK2 inhibitor nomelcitinib meets phase 3 psoriasis goals, with PASI 90 in over 70% of patients, InventisBio says
  InventisBio announced company-reported topline results from a randomized, double-blind, placebo-controlled phase 3 trial of nomelcitinib (D-2570), a JH2-selective TYK2 inhibitor, in psoriasis, according to BioPharma APAC. The trial randomized 391 patients 1:1:1 to two nomelcitinib groups or placebo; both groups reached the primary end point, PASI 90, in more than 70% of patients and PGA 0/1 in more than 80% (P < .0001 versus placebo), with no new safety signals, the company said. Doses and placebo rates were not reported, and the results have not been peer reviewed.
  Source: BioPharma APAC
• Research Nov 7, 2026
  Oral icotrokinra clears or nearly clears skin in 57% versus 14% with placebo in phase 3 psoriatic arthritis trial, J&J says
  Johnson & Johnson said Nov. 7 that in the phase 3 ICONIC-PsA 1 trial in biologic-naive adults with active psoriatic arthritis, 58% taking once-daily oral icotrokinra (Icotyde) reached an American College of Rheumatology 20 response at week 16, the primary end point, versus 41% with placebo. Among patients with plaque psoriasis on at least 3% of body surface area at baseline, 57% had clear or almost clear skin versus 14% (nominal P < .001). The company said there were no new safety signals; the drug is approved in the U.S. for moderate-to-severe plaque psoriasis but not for psoriatic arthritis.
  Source: Johnson & Johnson

The weekly innovation roundup for dermatology, published every Sunday for the week before; every item links to its sources. Latest dermatology news · All specialties